We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
151
Ardelyx
ARDX
$1.27B
– –
-252,198
Closed -$1.47M
ASND icon
152
Ascendis Pharma A/S
ASND
$17B
– –
-6,840
Closed -$1.46M
BBIO icon
153
CALL
BridgeBio Pharma
BBIO
$15.7B
– –
-139,600
Closed -$10.7M
BBIO icon
154
PUT
BridgeBio Pharma
BBIO
$15.7B
– –
-200,000
Closed -$15.3M
BCRX icon
155
BioCryst Pharmaceuticals
BCRX
$2.31B
– –
-190,928
Closed -$1.49M
BDTX icon
156
CALL
Black Diamond Therapeutics
BDTX
$104M
– –
-190,400
Closed -$463K
CNTA
157
CALL
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-21,100
Closed -$528K
CNTA
158
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-90,000
Closed -$2.25M
CORT icon
159
PUT
Corcept Therapeutics
CORT
$9.63B
– –
-134,800
Closed -$4.69M
CRVS icon
160
PUT
Corvus Pharmaceuticals
CRVS
$1.2B
– –
-53,100
Closed -$409K
DSGN icon
161
Design Therapeutics
DSGN
$788M
– –
-100,320
Closed -$941K
EDIT icon
162
CALL
Editas Medicine
EDIT
$442M
– –
-318,700
Closed -$653K
EDSA icon
163
Edesa Biotech
EDSA
$64.7M
– –
-54,025
Closed -$76.7K
EWTX icon
164
Edgewise Therapeutics
EWTX
$4.11B
– –
-30,000
Closed -$865K
GOSS icon
165
CALL
Gossamer Bio
GOSS
$83.3M
– –
-877,100
Closed -$2.72M
GPCR icon
166
CALL
Structure Therapeutics
GPCR
$3.27B
– –
-191,700
Closed -$13.3M
IMNM icon
167
Immunome
IMNM
$2.51B
– –
-22,500
Closed -$483K
INBX icon
168
Inhibrx
INBX
$1.31B
– –
-1,299
Closed -$103K
INDV icon
169
CALL
Indivior Pharmaceuticals
INDV
$4.8B
– –
-220,300
Closed -$7.9M
INSM icon
170
CALL
Insmed
INSM
$23.3B
– –
-52,800
Closed -$9.19M
IONS icon
171
CALL
Ionis Pharmaceuticals
IONS
$9.03B
– –
-106,200
Closed -$8.4M
IRWD icon
172
Ironwood Pharmaceuticals
IRWD
$637M
– –
-683,611
Closed -$2.3M
JAZZ icon
173
CALL
Jazz Pharmaceuticals
JAZZ
$15.2B
– –
-105,300
Closed -$17.9M
JNJ icon
174
CALL
Johnson & Johnson
JNJ
$602B
– –
-50,000
Closed -$10.3M
LEGN icon
175
CALL
Legend Biotech
LEGN
$4.39B
– –
-69,000
Closed -$1.5M
5 6
7
8 9

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.